CA3239571A1 - Fused pyrrolidine psychoplastogens and uses thereof - Google Patents

Fused pyrrolidine psychoplastogens and uses thereof Download PDF

Info

Publication number
CA3239571A1
CA3239571A1 CA3239571A CA3239571A CA3239571A1 CA 3239571 A1 CA3239571 A1 CA 3239571A1 CA 3239571 A CA3239571 A CA 3239571A CA 3239571 A CA3239571 A CA 3239571A CA 3239571 A1 CA3239571 A1 CA 3239571A1
Authority
CA
Canada
Prior art keywords
compound
optionally substituted
alkyl
disorder
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3239571A
Other languages
English (en)
French (fr)
Inventor
Noel Aaron Powell
Milan Chytil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Delix Therapeutics Inc
Original Assignee
Delix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delix Therapeutics Inc filed Critical Delix Therapeutics Inc
Publication of CA3239571A1 publication Critical patent/CA3239571A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3239571A 2021-12-15 2022-12-14 Fused pyrrolidine psychoplastogens and uses thereof Pending CA3239571A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163290037P 2021-12-15 2021-12-15
US63/290,037 2021-12-15
US202263387225P 2022-12-13 2022-12-13
US63/387,225 2022-12-13
PCT/US2022/052879 WO2023114320A1 (en) 2021-12-15 2022-12-14 Fused pyrrolidine psychoplastogens and uses thereof

Publications (1)

Publication Number Publication Date
CA3239571A1 true CA3239571A1 (en) 2023-06-22

Family

ID=86773439

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3239571A Pending CA3239571A1 (en) 2021-12-15 2022-12-14 Fused pyrrolidine psychoplastogens and uses thereof

Country Status (9)

Country Link
EP (1) EP4448532A4 (https=)
JP (1) JP2025502614A (https=)
KR (1) KR20240150418A (https=)
AU (1) AU2022415426A1 (https=)
CA (1) CA3239571A1 (https=)
IL (1) IL313457A (https=)
MX (1) MX2024007220A (https=)
TW (1) TW202333736A (https=)
WO (1) WO2023114320A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023014630A (es) 2021-06-08 2024-01-30 Atai Therapeutics Inc Activadores de dimetoxifenilalquilamina de receptores de serotonina.
IL313455A (en) 2021-12-15 2024-08-01 Delix Therapeutics Inc Phenoxy and benzyloxy modified psychroplastogens and their uses
EP4457203A4 (en) 2021-12-27 2025-12-17 Atai Therapeutics Inc AMINOTETRALINE ACTIVATORS OF SEROTONIN RECEPTORS
US12343319B2 (en) 2023-05-01 2025-07-01 Atai Therapeutics, Inc. Compositions and methods for treatment of diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0808312T3 (da) * 1995-02-02 2001-02-12 Smithkline Beecham Plc Indolderivater som 5-HT-receptorantagonist
AR023574A1 (es) * 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
WO2002024700A2 (en) * 2000-09-20 2002-03-28 Pharmacia & Upjohn Company SUBSTITUTED AZEPINO[4,5b]INDOLINE DERIVATIVES
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
WO2021076572A1 (en) * 2019-10-14 2021-04-22 The Regents Of The University Of California Ergoline-like compounds for promoting neural plasticity

Also Published As

Publication number Publication date
TW202333736A (zh) 2023-09-01
WO2023114320A1 (en) 2023-06-22
EP4448532A1 (en) 2024-10-23
KR20240150418A (ko) 2024-10-15
EP4448532A4 (en) 2025-12-24
AU2022415426A1 (en) 2024-07-25
JP2025502614A (ja) 2025-01-28
MX2024007220A (es) 2024-08-27
IL313457A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
CA3239571A1 (en) Fused pyrrolidine psychoplastogens and uses thereof
CA3182182A1 (en) Isotryptamine psychoplastogens and uses thereof
WO2021076572A1 (en) Ergoline-like compounds for promoting neural plasticity
CA3182093A1 (en) Tricyclic psychoplastogens and uses thereof
AU2020229779A1 (en) Azepino-indoles and other heterocycles for treating brain disorders
US12295959B2 (en) Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
WO2023114858A1 (en) Benzofuran and benzothiophene psychoplastogens and uses thereof
WO2023114238A1 (en) Aryloxy psychoplastogens and uses thereof
WO2024258995A2 (en) Fused tetrahydroazepine psychoplastogens and uses thereof
WO2023114325A1 (en) Constrained amine psychoplastogens and uses thereof
WO2023114844A1 (en) Imidazopyridine psychoplastogens and uses thereof
WO2024258988A2 (en) Serotonin releasing compounds and uses thereof
CN118696047A (zh) 稠合吡咯烷精神重塑剂及其用途
CN118742551A (zh) 苯氧基和苄氧基取代的精神重塑剂及其用途
WO2026072584A1 (en) Methods of using phenoxy and benzyloxy substituted neuroplastogens
CN116507625A (zh) 异色胺神经可塑剂及其用途
WO2025137639A1 (en) Mixed serotonin receptor binders for treatment of psychotic disorders

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206